Zimbabwe has declined a major American healthcare agreement worth $367m (£272m) over five years due to the United States' demand for confidential biological samples.
This rejection became public after a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesperson later stated that the US was requesting biological samples for research and profit but refused to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a deal acceptable to all parties so the nation's vital HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable situation in Kenya, where a court suspended a similar deal with the US after concerns were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
As per reports, 16 nations in Africa have to date agreed to similar agreements, representing over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the raw materials for medical research without any certainty that the end products would be accessible to our people if a new pandemic arise."
National Interest and Global Health
He also pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting structures previously established through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This system is intended to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
These objections regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to ongoing discussions with our US partners on how future co-operation might be arranged in a way that respects the independence and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that talks should continue since much of the country's HIV programmes relied on international support.
"In cases where technical issues exist, including those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it commented.
The halted deal underscores the complex debate between receiving much-needed foreign assistance and safeguarding a country's data in an increasingly interconnected world.